Medscape Medical News - August 28, 2012 - Joe Barber Jr, PhD
The daily addition of 75 g of whole-shelled walnuts to a typical
Western-style diet appears to have positive effects on the vitality,
morphology, and motility of sperm in healthy men, according to the
findings of a randomized, parallel, 2-group, dietary intervention trial.
The authors noted that this study could not clarify whether the effects
observed in healthy adults will be applicable to those with fertility
issues. "Whether adding walnuts to the diet will go beyond the shifts in
sperm parameters as seen in this study to improving birth outcomes for
men within fertility clinic populations or in the general population is
not yet known and will require further research," the authors write.
This study was funded through a grant from the California Walnut
Commission. Dr. Lamb has received grant support from the National
Institutes of Health and from the William and Ella Owens Medical
Research Foundation.
Read the full Medscape Report
(Free sign-up may be required)
Wednesday, August 29, 2012
Benefits of circumcision outweigh risks
Reuters - CHICAGO |
Mon Aug 27, 2012
"We're not saying you have to have it," said Dr. Andrew Freedman, a pediatric urologist at Cedars-Sinai Medical Center in Los Angeles who chaired the AAP's circumcision task force.
"We're saying if a family thinks it is in the child's best interests, the benefits are enough to help them do that," he said.
In a statement issued on Friday in anticipation of the guidelines, the anti-circumcision group Intact America said most of the studies underlying the new guidelines are based on research done on adult men in Africa.
"The task force has failed to consider the large body of evidence from the developed world that shows no medical benefits for the practice, and has given short shrift, if not dismissed out of hand, the serious ethical problems inherent in doctors removing healthy body parts from children who cannot consent," said Georganne Chapin, the group's executive director.
Read the full Reuters report
"We're not saying you have to have it," said Dr. Andrew Freedman, a pediatric urologist at Cedars-Sinai Medical Center in Los Angeles who chaired the AAP's circumcision task force.
"We're saying if a family thinks it is in the child's best interests, the benefits are enough to help them do that," he said.
In a statement issued on Friday in anticipation of the guidelines, the anti-circumcision group Intact America said most of the studies underlying the new guidelines are based on research done on adult men in Africa.
"The task force has failed to consider the large body of evidence from the developed world that shows no medical benefits for the practice, and has given short shrift, if not dismissed out of hand, the serious ethical problems inherent in doctors removing healthy body parts from children who cannot consent," said Georganne Chapin, the group's executive director.
Read the full Reuters report
Saturday, August 25, 2012
New prostate cancer study clouds PSA debate
Reuters Health - NEW YORK |
Fri Aug 24, 2012
A new study suggests men with advanced prostate cancer may live longer in the "PSA era" than they did before the screening test began to gain a foothold in the early 1990s.
The findings - which a leading cancer expert said were problematic - stoke the heated debate over prostate cancer screening using the prostate-specific antigen (PSA) test. Many researchers now fear routine testing may lead to aggressive treatments that do more harm than good.
"The translation of this is, might it very well be that for advanced prostate cancer finding it earlier may allow the earlier initiation of therapy that may then reduce the death rates from the disease?"
But the chief medical officer of the American Cancer Society, who was not involved in the work, said the study has a number of serious shortcomings.
Read the full Reuters Health report
A new study suggests men with advanced prostate cancer may live longer in the "PSA era" than they did before the screening test began to gain a foothold in the early 1990s.
The findings - which a leading cancer expert said were problematic - stoke the heated debate over prostate cancer screening using the prostate-specific antigen (PSA) test. Many researchers now fear routine testing may lead to aggressive treatments that do more harm than good.
"The translation of this is, might it very well be that for advanced prostate cancer finding it earlier may allow the earlier initiation of therapy that may then reduce the death rates from the disease?"
But the chief medical officer of the American Cancer Society, who was not involved in the work, said the study has a number of serious shortcomings.
Read the full Reuters Health report
Thursday, August 16, 2012
Study 'Shows the Way' to Resolving PSA Controversy
Medscape Medical News | August 15, 2012
A new approach to evaluating the benefits and harms of prostate-specific antigen (PSA) testing "shows the way to a resolution of the long-standing problem about screening for prostate cancer," according to an editorial in the August 16th edition of The New England Journal of Medicine.
The new study, which is derived from statistical modeling, found that the benefit of prostate cancer screening is "diminished" by the loss of quality-adjusted life-years caused by overdiagnosis and overtreatment.
Nevertheless, there is an average net benefit from screening in terms of quality-adjusted life-years, according to the study authors, who are led by Eveline Heijnsdijk, PhD, of the Erasmus Medical Center in the Netherlands.
Annual screening of those between the ages of 55 and 69 years would result in:
- 9 fewer deaths from prostate cancer (28% mortality reduction);
- 14 fewer men receiving palliative therapy (35% reduction);
- a total of 73 life-years gained (an average of 8.4 years per prostate cancer death avoided).
However, the total number of quality-adjusted life-years gained from screening in the group was lower (56 years) than the unadjusted (73 years) because of harms that men endure due to screening, they report. Screening would also result in 45 men being overdiagnosed and overtreated.
The authors calculated that to prevent one prostate cancer death, 98 men would have to be screened and 5 cancers would have to be detected.
Read the full Medscape Medical News report
(Free sign-up may be required)
A new approach to evaluating the benefits and harms of prostate-specific antigen (PSA) testing "shows the way to a resolution of the long-standing problem about screening for prostate cancer," according to an editorial in the August 16th edition of The New England Journal of Medicine.
The new study, which is derived from statistical modeling, found that the benefit of prostate cancer screening is "diminished" by the loss of quality-adjusted life-years caused by overdiagnosis and overtreatment.
Nevertheless, there is an average net benefit from screening in terms of quality-adjusted life-years, according to the study authors, who are led by Eveline Heijnsdijk, PhD, of the Erasmus Medical Center in the Netherlands.
Annual screening of those between the ages of 55 and 69 years would result in:
- 9 fewer deaths from prostate cancer (28% mortality reduction);
- 14 fewer men receiving palliative therapy (35% reduction);
- a total of 73 life-years gained (an average of 8.4 years per prostate cancer death avoided).
However, the total number of quality-adjusted life-years gained from screening in the group was lower (56 years) than the unadjusted (73 years) because of harms that men endure due to screening, they report. Screening would also result in 45 men being overdiagnosed and overtreated.
The authors calculated that to prevent one prostate cancer death, 98 men would have to be screened and 5 cancers would have to be detected.
Read the full Medscape Medical News report
(Free sign-up may be required)
Benefits of PSA testing may outweigh harms
Reuters Health | NEW YORK |
Wed Aug 15, 2012
The possible benefits and harms of prostate cancer screening have been hotly debated in recent years, but for the first time a new study tries to put a number on the balance of pluses and minuses for the average man.
Using data from past cancer studies and a mathematical model, researchers from the Netherlands calculated that on average, annual screening using prostate-specific antigen (PSA) testing would add three healthy weeks to a man's life.
Whether screening has a net benefit or harm for a particular man depends on how he feels about the possibility of suffering screening- and treatment-related side effects - and how much erectile dysfunction or incontinence, for example, would influence his quality of life
Researchers considered the benefits of catching some cancers early - including a lower chance of dying from prostate cancer - as well as the harms of so-called overdiagnosis. Cancers caught during screening are considered overdiagnosis if they never would have produced symptoms or threatened a man's lifespan. In those cases, treatment can cause side effects but won't do men any good.
While the European study showed a 29-percent reduction in the chance of dying from prostate cancer in men who were screened, another large trial from the U.S. failed to show any survival benefit.
I note that some of the researchers have received consulting fees from pharmaceutical and medical device companies, including a company that designs PSA tests.
Read the full Reuters Health report
The possible benefits and harms of prostate cancer screening have been hotly debated in recent years, but for the first time a new study tries to put a number on the balance of pluses and minuses for the average man.
Using data from past cancer studies and a mathematical model, researchers from the Netherlands calculated that on average, annual screening using prostate-specific antigen (PSA) testing would add three healthy weeks to a man's life.
Whether screening has a net benefit or harm for a particular man depends on how he feels about the possibility of suffering screening- and treatment-related side effects - and how much erectile dysfunction or incontinence, for example, would influence his quality of life
Researchers considered the benefits of catching some cancers early - including a lower chance of dying from prostate cancer - as well as the harms of so-called overdiagnosis. Cancers caught during screening are considered overdiagnosis if they never would have produced symptoms or threatened a man's lifespan. In those cases, treatment can cause side effects but won't do men any good.
While the European study showed a 29-percent reduction in the chance of dying from prostate cancer in men who were screened, another large trial from the U.S. failed to show any survival benefit.
I note that some of the researchers have received consulting fees from pharmaceutical and medical device companies, including a company that designs PSA tests.
Read the full Reuters Health report
Thursday, August 9, 2012
Robot prostatectomy cuts incontinence, surgeon finds
Reuters Health - NEW YORK |
Wed Aug 8, 2012
Robot surgery for prostate cancer lowered the rate of urinary complications compared with hands-on surgery in a new Italian study.
While the study was small and contradicts earlier results, it's important because robot surgery has quickly overtaken cheaper alternatives in the U.S., helped by hospitals aggressively marketing the technology.
Cooperberg said surgeon skill and experience is more important than the technology they use. Patients, he added, should not be afraid to ask their surgeon about his or her outcomes.
And that, perhaps, is the strongest conclusion from the new report.
Read the full Reuters Health report
Robot surgery for prostate cancer lowered the rate of urinary complications compared with hands-on surgery in a new Italian study.
While the study was small and contradicts earlier results, it's important because robot surgery has quickly overtaken cheaper alternatives in the U.S., helped by hospitals aggressively marketing the technology.
Cooperberg said surgeon skill and experience is more important than the technology they use. Patients, he added, should not be afraid to ask their surgeon about his or her outcomes.
And that, perhaps, is the strongest conclusion from the new report.
Read the full Reuters Health report
Wednesday, August 8, 2012
Statins Don't Cut Prostate Cancer Recurrence After Prostatectomy
NEW YORK (Reuters Health) Aug 01 -
Statin users did not have a lower rate of biochemical recurrence after radical prostatectomy in a recent study.
"Prostate cancer can be a very aggressive disease, and we are all looking for a golden bullet to stop it in its tracks," Dr. Alon Y. Mass from New York University School of Medicine in New York City told Reuters Health by email.
"We entered this study being hopeful that we may be able to isolate a viable therapy to combat the progression of prostate cancer after prostatectomy. Unfortunately, statins don't seem to be the answer."
Read the full Reuteurs Health report via Medscape Today
(Free sign-up may be required)
Statin users did not have a lower rate of biochemical recurrence after radical prostatectomy in a recent study.
"Prostate cancer can be a very aggressive disease, and we are all looking for a golden bullet to stop it in its tracks," Dr. Alon Y. Mass from New York University School of Medicine in New York City told Reuters Health by email.
"We entered this study being hopeful that we may be able to isolate a viable therapy to combat the progression of prostate cancer after prostatectomy. Unfortunately, statins don't seem to be the answer."
Read the full Reuteurs Health report via Medscape Today
(Free sign-up may be required)
Subscribe to:
Posts (Atom)